Filing Details

Accession Number:
0000914062-13-000239
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-10-09 17:12:08
Reporting Period:
2013-10-07
Filing Date:
2013-10-09
Accepted Time:
2013-10-09 17:12:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1456614 D Rod Martin C/O Galectin Therapeutics, Inc.
4960 Peachtree Industrial Blvd, Ste 240
Newton MA 02459
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-10-07 100,000 $11.79 8,969,422 No 4 S Indirect By 10X Fund, L.P.
Common Stock Disposition 2013-10-08 12,000 $12.36 8,957,422 No 4 S Indirect By 10X Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By 10X Fund, L.P.
No 4 S Indirect By 10X Fund, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 91,488 Direct
Footnotes
  1. Reflects weighted average price. Range of prices were between $11.5335 and $12.136. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  2. Reflects weighted average price. Range of prices were between $12.00 and $12.51. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  3. Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.